ClinicalTrials.gov
ClinicalTrials.gov Menu

Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02829164
Recruitment Status : Recruiting
First Posted : July 12, 2016
Last Update Posted : May 23, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:
Primitive kidney disease IgA, represented by Berger's disease and rheumatoid purpura nephropathy, are the first cause of kidney failure from chronic glomerulonephritis: changes in 20 years to end-stage renal failure is described in 10 to 30 % of cases in Berger's disease and in 15 to 20% of cases in nephropathy HSP. These two pathological entities share biological and histological characteristics, as well as common pathophysiological mechanisms, particularly the production of abnormally glycosylated IgA1 promoting their proliferation in the mesangium. Tonsils part of Iga abnormal production sites that would be associated with an infectious stimulus, tonsillectomy has been studied as a possible treatment in primitive IgA nephropathy. The benefit of tonsillectomy is controversial: many Japanese studies demonstrate its effectiveness in terms of reduction of proteinuria, improved renal function in the long term regression of histological lesions and reduced risk of relapse following clinical remission whereas European studies do not suggest its effectiveness in treating IgA nephropathy. In this context, the aim of our study is to describe the scope of practice of tonsillectomy in the treatment of primary renal disease in IgA child in the inter East region and describe the short renal become Strasbourg end of the cohort that received this treatment.

Condition or disease
Tonsillectomy

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region
Actual Study Start Date : April 2016
Estimated Primary Completion Date : September 2017
Estimated Study Completion Date : September 2017

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Evaluation of the management of the tonsillectomy at the CHU of Strasbourg by a standardized questionnaire [ Time Frame: since January 2009 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children with a clinical diagnosis and / or histological evidence of primary IgA nephropathy
Criteria

Inclusion criteria:

  • Children with a clinical diagnosis and / or histological evidence of primary IgA nephropathy
  • Follow the University Hospital of Strasbourg since 2009
  • Having received a tonsillectomy in their care
  • Children whose holders of parental authority does not oppose the use of clinical data from their child for research purposes

Exclusion criteria:

  • Children whose holders of parental authority are opposed to the use of clinical data from their child for research purposes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02829164


Contacts
Contact: Laetitia HIGEL, MD 33 (0)3.88.12.77.40 laetitia.higel@chru-strasbourg.fr
Contact: Eléonore FEUGEAS, MD 33 (0)3.88.12.77.40 Eleonore.feugeas@chru-strasbourg.fr

Locations
France
Service de Pédiatrie 1 Hôpital de Hautepierre Recruiting
Strasbourg, France, 67098
Contact: Laetitia HIGEL, MD    33 (0)3.88.12.77.40    laetitia.higel@chru-strasbourg.fr   
Contact: Eléonore FEUGEAS, MD    33 (0)3.88.12.77.40    Eleonore.feugeas@chru-strasbourg.fr   
Principal Investigator: Laetitia HIGEL, MD         
Sub-Investigator: Eléonore FEUGEAS, MD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Laetitia HIGEL, MD University Hospital, Strasbourg, France

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT02829164     History of Changes
Other Study ID Numbers: 6402
First Posted: July 12, 2016    Key Record Dates
Last Update Posted: May 23, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by University Hospital, Strasbourg, France:
Tonsillectomy
primary IgA nephropathy
primary nephropathy
IgA
Berger's disease
Purpura rheumatoid
kidney failure

Additional relevant MeSH terms:
Kidney Diseases
Glomerulonephritis, IGA
Urologic Diseases
Glomerulonephritis
Nephritis
Autoimmune Diseases
Immune System Diseases